Current and Emerging Cell Culture Manufacturing Technologies for Influenza Vaccines
Published 2015 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Current and Emerging Cell Culture Manufacturing Technologies for Influenza Vaccines
Authors
Keywords
-
Journal
Biomed Research International
Volume 2015, Issue -, Pages 1-11
Publisher
Hindawi Limited
Online
2015-03-02
DOI
10.1155/2015/504831
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Influenza reverse genetics: dissecting immunity and pathogenesis
- (2014) Siying Ye et al. EXPERT REVIEWS IN MOLECULAR MEDICINE
- Traditional and New Influenza Vaccines
- (2013) S.-S. Wong et al. CLINICAL MICROBIOLOGY REVIEWS
- Safety and immunogenicity of an oral, replicating adenovirus serotype 4 vector vaccine for H5N1 influenza: a randomised, double-blind, placebo-controlled, phase 1 study
- (2013) Marc Gurwith et al. LANCET INFECTIOUS DISEASES
- Clinical Assessment of a Novel Recombinant Simian Adenovirus ChAdOx1 as a Vectored Vaccine Expressing Conserved Influenza A Antigens
- (2013) Richard D Antrobus et al. MOLECULAR THERAPY
- Broadly Protective Adenovirus-Based Multivalent Vaccines against Highly Pathogenic Avian Influenza Viruses for Pandemic Preparedness
- (2013) Sai V. Vemula et al. PLoS One
- Oral administration of an adenovirus vector encoding both an avian influenza A hemagglutinin and a TLR3 ligand induces antigen specific granzyme B and IFN-γ T cell responses in humans
- (2013) Wendy Peters et al. VACCINE
- Vaccine process technology
- (2012) Jessica O. Josefsberg et al. BIOTECHNOLOGY AND BIOENGINEERING
- A Cell Culture-Derived Influenza Vaccine Provides Consistent Protection Against Infection and Reduces the Duration and Severity of Disease in Infected Individuals
- (2012) H. J. Ehrlich et al. CLINICAL INFECTIOUS DISEASES
- Many ways to make an influenza virus - review of influenza virus reverse genetics methods
- (2012) Othmar G. Engelhardt Influenza and Other Respiratory Viruses
- Identification of Novel Influenza A Virus Proteins Translated from PA mRNA
- (2012) Y. Muramoto et al. JOURNAL OF VIROLOGY
- Pre-Clinical Evaluation of a Replication-Competent Recombinant Adenovirus Serotype 4 Vaccine Expressing Influenza H5 Hemagglutinin
- (2012) Jeff Alexander et al. PLoS One
- A distinct lineage of influenza A virus from bats
- (2012) S. Tong et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- An Overlapping Protein-Coding Region in Influenza A Virus Segment 3 Modulates the Host Response
- (2012) B. W. Jagger et al. SCIENCE
- New technologies for new influenza vaccines
- (2012) Alan Shaw VACCINE
- Safety and immunogenicity of a quadrivalent inactivated influenza vaccine compared to licensed trivalent inactivated influenza vaccines in adults
- (2012) David P. Greenberg et al. VACCINE
- Global production capacity of seasonal influenza vaccine in 2011
- (2012) Jeffrey Partridge et al. VACCINE
- New technologies for influenza vaccines
- (2012) Philip Dormitzer et al. Human Vaccines & Immunotherapeutics
- A fast track influenza virus vaccine produced in insect cells
- (2011) Manon M.J. Cox et al. JOURNAL OF INVERTEBRATE PATHOLOGY
- Large-scale production and purification of VLP-based vaccines
- (2011) Tiago Vicente et al. JOURNAL OF INVERTEBRATE PATHOLOGY
- Efficacy, safety, and immunogenicity of a Vero-cell-culture-derived trivalent influenza vaccine: a multicentre, double-blind, randomised, placebo-controlled trial
- (2011) P Noel Barrett et al. LANCET
- Adenovirus-Vectored Drug-Vaccine Duo as a Rapid-Response Tool for Conferring Seamless Protection against Influenza
- (2011) Jianfeng Zhang et al. PLoS One
- Safety and immunogenicity of a virus-like particle pandemic influenza A (H1N1) 2009 vaccine in a blinded, randomized, placebo-controlled trial of adults in Mexico
- (2011) Constantino López-Macías et al. VACCINE
- Evaluation of the safety, reactogenicity and immunogenicity of FluBlok® trivalent recombinant baculovirus-expressed hemagglutinin influenza vaccine administered intramuscularly to healthy adults 50–64 years of age☆
- (2011) R. Baxter et al. VACCINE
- Clinical development of a Vero cell culture-derived seasonal influenza vaccine
- (2011) Hartmut J. Ehrlich et al. VACCINE
- Process optimization and scale-up for production of rabies vaccine live adenovirus vector (AdRG1.3)
- (2011) Chun Fang Shen et al. VACCINE
- Production of cell culture (MDCK) derived live attenuated influenza vaccine (LAIV) in a fully disposable platform process
- (2010) Meena George et al. BIOTECHNOLOGY AND BIOENGINEERING
- Influenza Virus Evolution, Host Adaptation, and Pandemic Formation
- (2010) Jeffery K. Taubenberger et al. Cell Host & Microbe
- Production of adenovirus vectors and their use as a delivery system for influenza vaccines
- (2010) Sai V Vemula et al. EXPERT OPINION ON BIOLOGICAL THERAPY
- Scalable production of influenza virus in HEK-293 cells for efficient vaccine manufacturing
- (2010) Audrey Le Ru et al. VACCINE
- NS-based live attenuated H1N1 pandemic vaccines protect mice and ferrets
- (2010) Bin Zhou et al. VACCINE
- Structure-based design of NS2 mutants for attenuated influenza A virus vaccines
- (2010) Hatice Akarsu et al. VIRUS RESEARCH
- FluBlok, a next generation influenza vaccine manufactured in insect cells
- (2009) Manon M.J. Cox et al. BIOLOGICALS
- Trivalent MDCK cell culture-derived influenza vaccine Optaflu®(Novartis Vaccines)
- (2009) Alexander Doroshenko et al. Expert Review of Vaccines
- Adenovirus as a carrier for the development of influenza virus-free avian influenza vaccines
- (2009) De-chu C Tang et al. Expert Review of Vaccines
- Vero cell platform in vaccine production: moving towards cell culture-based viral vaccines
- (2009) P Noel Barrett et al. Expert Review of Vaccines
- Continuous cell lines as a production system for influenza vaccines
- (2009) Yvonne Genzel et al. Expert Review of Vaccines
- Subunit Influenza Vaccines Produced from Cell Culture or in Embryonated Chicken Eggs: Comparison of Safety, Reactogenicity, and Immunogenicity
- (2009) Keith S. Reisinger et al. JOURNAL OF INFECTIOUS DISEASES
- A Novel Type of Influenza Vaccine: Safety and Immunogenicity of Replication‐Deficient Influenza Virus Created by Deletion of the Interferon Antagonist NS1
- (2009) Volker Wacheck et al. JOURNAL OF INFECTIOUS DISEASES
- A Complicated Message: Identification of a Novel PB1-Related Protein Translated from Influenza A Virus Segment 2 mRNA
- (2009) H. M. Wise et al. JOURNAL OF VIROLOGY
- Preclinical Evaluation of a Replication-Deficient Intranasal ΔNS1 H5N1 Influenza Vaccine
- (2009) Julia Romanova et al. PLoS One
- Use of MDCK cells for production of live attenuated influenza vaccine
- (2009) Jonathan Liu et al. VACCINE
- Evaluation of the safety, reactogenicity and immunogenicity of FluBlok® trivalent recombinant baculovirus-expressed hemagglutinin influenza vaccine administered intramuscularly to healthy children aged 6–59 months
- (2009) James C. King et al. VACCINE
- Current challenges in implementing cell-derived influenza vaccines: Implications for production and regulation, July 2007, NIBSC, Potters Bar, UK
- (2009) Philip D. Minor et al. VACCINE
- Influenza vaccines
- (2009) A.H. Ellebedy et al. VACCINE
- Live Attenuated Influenza Viruses Containing NS1 Truncations as Vaccine Candidates against H5N1 Highly Pathogenic Avian Influenza
- (2008) J. Steel et al. JOURNAL OF VIROLOGY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now